article Refreshing how we approach neuroscience with a novel screening technology 9 April 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
news New imaging technique developed to study fungi 9 April 2020 | By Victoria Rees (Drug Target Review) German researchers have developed a novel imaging technique called expansion microscopy (ExM) to investigate fungi samples.
article Gender-specific coronavirus infections in the light of evolution 9 April 2020 | By Dr Ulrich Kutschera (University of Kassel) Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
news Human lung epithelium model being tested as a platform for COVID-19 research 9 April 2020 | By Hannah Balfour (Drug Target Review) The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
news Transplanted reprogrammed skin cells repair stroke-damaged rat brains 9 April 2020 | By Hannah Balfour (Drug Target Review) Skin cells reprogrammed into nerves and transplanted into the stroke-damaged rat brains formed functional connections that restored mobility and touch sensation.
article COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine? 9 April 2020 | By Victoria Rees (Drug Target Review) A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
news MERS vaccine candidate could hold promise for COVID-19 vaccine 8 April 2020 | By Hannah Balfour (Drug Target Review) The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
news IL-27 could work as potential immunotherapy against cancers 8 April 2020 | By Victoria Rees (Drug Target Review) Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
news Receptors enabling COVID-19 infection found on cilia progenitor cells, study shows 8 April 2020 | By Victoria Rees (Drug Target Review) Sequencing almost 60,000 cells, researchers have found that certain cilia progenitor cells have gene transcripts for ACE2 and co-factor TMPRSS2, enabling COVID-19 infection.
news AI and cloud computing used to develop COVID-19 vaccine 8 April 2020 | By Victoria Rees (Drug Target Review) A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells.
news Novel ligands developed with high affinity for Alzheimer’s receptors 7 April 2020 | By Victoria Rees (Drug Target Review) A group of researchers has synthesised a new class of ligands which bind with high affinity to imidazoline I2 receptors, a drug target for Alzheimer's disease.
news EIDD-2801 shows efficacy against COVID-19 in human cells and mice 7 April 2020 | By Hannah Balfour (Drug Target Review) Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
news Researchers reveal how SARS antibody binds to COVID-19 coronavirus 7 April 2020 | By Victoria Rees (Drug Target Review) The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
article Predicting which diabetes treatments will reach clinical trials 7 April 2020 | By Victoria Rees (Drug Target Review) Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
news Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19 6 April 2020 | By Hannah Balfour (Drug Target Review) Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
